Jaguar health leveraging ai to support patient access to mytesi, the company's fda-approved prescription drug

Ai technology is expected to help make it faster and easier for mytesi® patients to start and stay on the drug san francisco, ca / accesswire / march 13, 2023 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced that the company is developing an artificial intelligence-powered web portal for u.s. healthcare professionals to support patient access to mytesi (crofelemer), the company's fda-approved antidiarrheal prescription drug indicated for the symptomatic relief of noninfectious diarrhea in adult patients with hiv/aids on antiretroviral therapy. "we remain committed to reducing access and reimbursement barriers for mytesi patients.
JAGX Ratings Summary
JAGX Quant Ranking